News releases from Pulmonx Corporation
Pulmonx to Report Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021
February 16, 2021
Pulmonx Welcomes Two New Members to Its Board of Directors, Adding Expertise in Consumer Marketing and Medical Device Company Growth
December 08, 2020
Georgia Garinois-Melenikiotou and Thomas W. Burns Joined the Pulmonx Board in October in Connection with the Company’s Initial Public Offering
Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD
November 30, 2020
Pulmonx Reports Third Quarter 2020 Financial Results
November 10, 2020
Pulmonx to Present at Upcoming Investor Conferences
November 03, 2020
Pulmonx Announces Additional 16 Million Covered Lives for The Zephyr® Valve, a Minimally Invasive Treatment Option for Severe Emphysema (COPD)
November 02, 2020
Positive Coverage Policy from Health Care Service Corporation (HCSC) Covers Blue Cross Blue Shield Members in Illinois, Montana, New Mexico, Oklahoma and Texas
Pulmonx Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
October 05, 2020
Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering
September 30, 2020
Pulmonx Announces National Reimbursement in France for Zephyr Endobronchial Valves, a Revolutionary Treatment Option for Patients With Severe Emphysema/COPD
May 18, 2020
The French Health Ministry has granted national reimbursement for the Zephyr Endobronchial Valve for COPD/emphysema.
A New Report Confirms Significant Benefits in Patient Reported Outcomes at One Year Following the Non-Surgical Zephyr Valve Procedure for COPD/Emphysema
May 12, 2020
ATS Report Confirms Significant Benefits in Patient Reported Outcomes at One Year Following the Non-Surgical Zephyr Valve Procedure for COPD/Emphysema
Pulmonx Secures $66M in Financing to Support Commercial Acceleration of the Zephyr Valve System, a Minimally-Invasive Treatment for Severe Emphysema
May 05, 2020
Pulmonx announces a $66 million financing round to support the continued global commercial expansion of the Zephyr Valve System for COPD / emphysema.
Pulmonx Names Industry Veteran to Board of Directors
February 26, 2020
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, today announced that Daniel Florin has joined its...
Pulmonx Announces that UnitedHealthcare, the Largest Commercial Insurer in the United States, Has Lifted Coverage Restrictions on the Zephyr Valve, a Minimally-Invasive Treatment Option for Severe Emp
November 18, 2019
Both UnitedHealthcare® and EmblemHealth recently announced positive coverage updates for Endobronchial Valve Treatments like the Zephyr Valve
The New 2020 Report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Gives Highest Evidence Rating to Endobronchial Valves, including the Zephyr Valve, for Treatment of Emphysema
November 11, 2019
GOLD’s evidence “A” rating affirms that endobronchial valves, like the Zephyr Valve, are a proven, viable treatment for COPD/Emphysema
Pulmonx Announces that Priority Health Now Covers the Zephyr Valve, a Less Invasive Treatment Option for Severe Emphysema (COPD)
August 28, 2019
Priority Health Now Covers the Zephyr Valve, a Less Invasive Treatment Option for Severe Emphysema (COPD).
Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies, announced today the closing of an oversubscribed $65 million equity financing and the hiring of Derrick...
Pulmonx Announces That HUMANA Has Issued a Positive Coverage Policy for the Zephyr Valve, a Less Invasive Treatment Option for Severe Emphysema (COPD)
April 30, 2019
The Zephyr® Valve, a less invasive treatment option for severe emphysema (COPD), is now covered by Humana, a national insurer with 10 million members.
New StratX Lung Analysis Platform from Pulmonx Enables Confident and Rapid Patient Selection for Zephyr Endobronchial Valve Treatment
September 01, 2016
Pulmonx launches StratX Lung Analysis Platform in Europe to enable confident and rapid patient selection for the Zephyr Endobronchial Valve.
STELVIO Trial Shows Sustained Benefits for Emphysema Patients One Year after Treatment with Pulmonx's Zephyr Endobronchial Valves
May 18, 2016
At ATS today, Pulmonx announced one-year data from the STELVIO trial showing sustained benefits and a high responder rate for the Zephyr Endobronchial Valve for emphysema.
New England Journal of Medicine Publishes Groundbreaking Study Demonstrating Benefits of Pulmonx's Medical Device for Emphysema
December 09, 2015
The New England Journal of Medicine published a study of the Zephyr Endobronchial Valve that shows superiority for the medical device when compared to medical management in treating severe emphysema.
Pulmonx Announces New President and CEO Michael A. Baker to Lead Interventional Pulmonology Company
July 15, 2009
From PR Newswire